SCNI Stock News & Catalysts – Scinai Immunotherapeutics

FEATURED

Scinai Reports Significant Revenue Growth in First Nine Months of 2026 as CDMO Business Expands

October agreement advances the U.S. customer program to approximately $5.1 million in committed base servicesJERUSALEM, Nov. 5, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai" or the

Summary

Nov 5, 2026, 8:00 AM ·PRNewswire

RECENT

Scinai CEO Updates Shareholders on CDMO Growth and Extended Runway Following Completed Financing

Management estimates operating runway to late 2027, with potential extension into the third quarter of 2028 as later project phases under the recently announced CDMO agreement are activated and deliveredJERUSALEM, Oct.

Oct 20, 2026, 8:49 AM ·PRNewswire

Scinai Immunotherapeutics Announces Closing of $4.0 Million Financing Through a Private Placement and Warrant Inducement

JERUSALEM, Oct. 16, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai" or the "Company"), a biopharmaceutical company operating a growing contract development and manufacturing

Oct 16, 2026, 8:00 AM ·PRNewswire

Scinai Immunotherapeutics Announces $4.0 Million Financing Through a Private Placement and Warrant Inducement

JERUSALEM, October 14, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai" or the "Company"), a biopharmaceutical company operating a growing contract development and

Oct 14, 2026, 8:00 AM ·PRNewswire

Scinai Expands CDMO Business with $5.1 Million Development and Clinical Manufacturing Agreement

Committed Customer Orders¹ reach approximately $7.6 million, up approximately 300% from $1.9 million at year-end 2025Agreement with a U.S. based, Nasdaq-listed biopharmaceutical company supports development activity in

Oct 13, 2026, 7:00 AM ·PRNewswire

Scinai Regains Compliance with Nasdaq Minimum Bid Price Requirement

Nasdaq confirms compliance with Listing Rule 5550(a)(2) after 19 consecutive business days with a closing bid price at or above $1.00; minimum bid price matter is closed JERUSALEM, Sept. 21, 2026 /PRNewswire/ -- Scinai

Sep 21, 2026, 7:00 AM ·PRNewswire

Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business

Following the conclusion of the PinCell option and license arrangements, Scinai concentrates resources on its NanoAb platform and CDMO commercial execution, without taking on additional PC111 funding commitments

Sep 8, 2026, 9:18 AM ·PRNewswire

Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum

Investor webinar scheduled for August 26, 2026 at 11:00 a.m. EDTJERUSALEM, Aug. 24, 2026 /PRNewswire/ – Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai" or the "Company"), a biopharmaceutical

Aug 24, 2026, 7:00 AM ·PRNewswire

Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration

Appointment strengthens operational infrastructure and supports integration and scale-up of Scinai's expanded CDMO platform.JERUSALEM, Aug. 10, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI)

Aug 10, 2026, 6:34 AM ·PRNewswire

Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives

JERUSALEM, June 10, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI), ("Scinai" or the "Company"), a biopharmaceutical company combining innovative therapeutic development with a

Jun 10, 2026, 7:55 AM ·PRNewswire

Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility

JERUSALEM, May 20, 2026 /PRNewswire/ – Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI), ("Scinai" or the "Company"), a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology

May 20, 2026, 7:00 AM ·PRNewswire

Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe

JERUSALEM, May 15, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI), ("Scinai" or the "Company") a biopharmaceutical company focused on inflammation and immunology, today announced that

May 15, 2026, 8:05 AM ·PRNewswire

Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing

Financing led by institutional life sciences investor, with participation from new and existing investorsCapital expected to support expansion of CDMO platform and advancement of customer programsJERUSALEM, April 24,

Apr 24, 2026, 8:00 AM ·PRNewswire

Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities

JERUSALEM, April 6, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI); ("Scinai" or the "Company"), a biopharmaceutical company developing inflammation and immunology therapeutics and

Apr 6, 2026, 7:00 AM ·PRNewswire

Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration

JERUSALEM, April 1, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI); ("Scinai" or the "Company"), a biopharmaceutical company operating a dual R&D and CDMO business model designed to

Apr 1, 2026, 7:35 AM ·PRNewswire

Scinai Immunotherapeutics Ltd. SCNI · News